Cullinan Therapeutics (CGEM) said Wednesday that the European Medicines Agency has approved its application to conduct a phase 1 clinical trial for CLN-978 to potentially treat rheumatoid arthritis.
The biopharmaceutical company said the open-label trial will be initiated in Q2 to assess the safety, pharmacokinetics, pharmacodynamics, and effects of CLN-978 in patients with active, difficult-to-treat rheumatoid arthritis.
Cullinan said the study will be held at FAU Erlangen-Nuremberg in Germany and Universita Cattolica del Sacro Cuore in Rome, the company added.
Price: 7.70, Change: -0.10, Percent Change: -1.28
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。